Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 1.18% is 37% below its 5-year average of 1.87%, around the middle of its 5-year range (-6.41%–11.42%).
140.34% above its 12-month average of -2.92%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.37%.
RETURN ON ASSETS (ROA)
1.18%
RETURN ON ASSETS (ROA) AVG TTM
-2.92%
RETURN ON ASSETS (ROA) AVG 3Y
-0.56%
RETURN ON ASSETS (ROA) AVG 5Y
1.87%
RETURN ON ASSETS (ROA) AVG 10Y
-0.56%
RETURN ON ASSETS (ROA) AVG 15Y
-8.47%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+140.34%
CURRENT VS 3Y AVG
+310.71%
CURRENT VS 5Y AVG
-36.79%
CURRENT VS 10Y AVG
+309.69%
CURRENT VS 15Y AVG
+113.94%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.94%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
+103.69%
vs the sector median at left
Pacira BioSciences, Inc.
Market Cap
$973.15M
Return on Assets (ROA)
1.18%
TTM Avg
-2.92%
3Y Avg
-0.56%
5Y Avg
1.87%
Market Cap
$968.25M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
Market Cap
$981.89M
Return on Assets (ROA)
-23.69%
TTM Avg
-98.11%
3Y Avg
-69.18%
5Y Avg
-69.18%
Market Cap
$983.53M
Return on Assets (ROA)
-22.90%
TTM Avg
-17.96%
3Y Avg
-22.57%
5Y Avg
-25.02%
Market Cap
$984.44M
Return on Assets (ROA)
19.92%
TTM Avg
-50.75%
3Y Avg
-41.99%
5Y Avg
-34.79%
Market Cap
$943.74M
Return on Assets (ROA)
-30.07%
TTM Avg
-30.07%
3Y Avg
-30.07%
5Y Avg
-30.07%
Market Cap
$950.86M
Return on Assets (ROA)
-72.50%
TTM Avg
-45.97%
3Y Avg
-37.50%
5Y Avg
-37.52%
Market Cap
$990.42M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$999.19M
Return on Assets (ROA)
130.50%
TTM Avg
-115.89%
3Y Avg
-79.68%
5Y Avg
-67.37%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | $973.15M | 1.18% | -2.92% | -0.56% | 1.87% |
| Aktis Oncology, Inc. (AKTS)vs › | $968.25M | -13.12% | -18.77% | -18.48% | -18.48% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $981.89M | -23.69% | -98.11% | -69.18% | -69.18% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $983.53M | -22.90% | -17.96% | -22.57% | -25.02% |
| MeiraGTx Holdings plc (MGTX)vs › | $984.44M | 19.92% | -50.75% | -41.99% | -34.79% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $943.74M | -30.07% | -30.07% | -30.07% | -30.07% |
| Savara Inc. (SVRA)vs › | $950.86M | -72.50% | -45.97% | -37.50% | -37.52% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $990.42M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $999.19M | 130.50% | -115.89% | -79.68% | -67.37% |
| Kura Oncology, Inc. (KURA)vs › | $937.68M | -50.49% | -30.32% | -31.10% | -27.11% |
ROA
1.2%
ROE
2.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 0.56% |
| 2024-12-31 | -6.41% |
| 2023-12-31 | 2.66% |
| 2022-12-31 | 0.95% |
| 2021-12-31 | 2.02% |
| 2020-12-31 | 11.42% |
| 2019-12-31 | -1.33% |
| 2018-12-31 | -0.07% |
| 2017-12-31 | -6.78% |
| 2016-12-31 | -9.69% |
| 2015-12-31 | 0.48% |
| 2014-12-31 | -4.21% |
| 2013-12-31 | -37.63% |
| 2012-12-31 | -46.66% |
| 2011-12-31 | -38.18% |
| 2010-12-31 | -40.79% |
| 2009-12-31 | -72.14% |
| 2008-12-31 | -82.83% |
